Adult bone marrow (BM) is a rich reservoir for endothelial
Introduction
Emerging data suggest that adult BM is a major reservoir for organ-specific stem cells, including hematopoietic stem cells (HSCs), 1 endothelial progenitors, 2 neuronal 3 and muscle stem cells. [4] [5] [6] [7] One of the most extensively studied pluripotent stem cell in the BM is HSCs. Adult BM contains a rare population of multi-potent HSC that have the capacity to undergo self-renewal and differentiate into all blood cell types. [8] [9] [10] [11] [12] Identification of HSCspecific surface molecules including, CD34 13, 14 and AC133, 15, 16 as well as in vivo and in vitro functional assays have enabled isolation and characterization of a pure population of HSC. [9] [10] [11] 17 Transplantation of a limited amount of this population of stem cells provide sufficient repopulating cells that can reconstitute hematopoiesis in lethally irradiated recipients. In addition, our group [18] [19] [20] [21] and others [22] [23] [24] [25] have identified a unique population of BM-derived circulating endothelial progenitors cells (CEPs, also known as EPCs) that have the capacity to 
ation process. Based on these studies, it has become apparent that mobilization of stem cells is a dynamic process and requires sequential release of chemocytokines, expression of adhesion molecules and activation of proteases that facilitate egress of cells from the BM to the circulation. Chemokine-activation of metalloproteinases is essential for the release of bio-active cytokines, thereby enhancing stem cell mobilization potential. Advectors are ideal for delivery of chemocytokines since they allow for long-term robust expression facilitating in vivo proliferation and mobilization of large numbers of an otherwise rare population of stem cells. VEGF-mobilized endothelial and hematopoietic stem cells provide for an enriched source of adult pluripotent cells that can be used for revascularization, tissue regeneration or gene therapy.
Gene Therapy (2002) 9, 631-641. DOI: 10.1038/sj/gt/3301723 mobilize to the circulation and contribute to tissue revascularization.
Isolation and purification of HSCs, CEPs or other organ-specific stem cells have been hampered because of low frequency and lack of specific marker that can facilitate isolation of this scarce population of cells. Furthermore, despite recent advancements in understanding the biology of HSC and CEPs, the in vitro and in vivo conditions that will allow for optimal expansion and mobilization of undifferentiated HSCs and CEPs are not well established.
Future success of any gene therapy strategy for the treatment of congenital hematological and vascular disorders will most likely depend on efficient expansion, mobilization and isolation of organ-specific stem cells, including pluripotent HSCs or CEPs. Presently, several cytokines and chemokines, including G-CSF, GM-CSF and certain angiogenic factors, including vascular endothelial growth factor (VEGF), alone or in combination have been shown to promote the mobilization of HSCs and CEPs.
Our group have used adenoviral vectors (Advectors) to deliver stem cell-active chemokines to promote the mobilization of a large number of stem cells from the murine BM. This murine mobilization model has facilitated execution of studies to decipher the mechanism and identify the cellular mediators that orchestrate stem cell mobilization. Characterization of the mechanism by which chemokines promote the mobilization of CEPs, HSCs and organ-specific stem cells will lay the foundation for optimizing the recovery of highly pluripotent stem cells, that may be used for tissue regeneration, revascularization, as well as gene therapy.
Role of stem cell active cytokines in the regulation of self-renewal, proliferation and mobilization of HSC
One of the most challenging aspects of stem cell biology is the identification of factors that support the selfrenewal, survival and motility of these cells. Several factors, such as, Flk-2 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] and Kit-ligand (stem cell factor) [39] [40] [41] have been shown to support the short-term survival and in vitro expansion of human, as well as murine HSCs ( Figure 1 ). However, given that any combination of known cytokines fails to support long-term proliferation and survival of stem cells in vitro, 42 there is no doubt that as yet unrecognized or novel factors provided within the BM environment support the self-renewal, survival and cell fate decisions of stem cells in vivo.
Among the known stem cell-active cytokines, expressed by BM stromal cells that mediate adhesion, motility and survival of HSC cells is the Kit-ligand (KitL) 43, 44 ( Figure 1 ). KitL, that can exist in both membrane (mKitL) and soluble form (sKitL), through interaction with its cognate tyrosine kinase receptor, c-Kit, supports the survival and motility of phenotypically marked Sca-1
-HSC. 45, 46 Emerging studies suggest that mKitL and sKitL may function differently in various physiological setting. Other stem cell-active cytokines that may play a role in vitro to promote expansion of bona fide HSCs are Flk-2 ligand, thrombopoietin and angiogenic factors, including VEGF. However, the cellular and molecular mediators that are activated by these chemokines and cytokines that promote mobilization of stem cells are not well known. 
Adhesion molecules involved in trafficking of HSC
In adulthood, hematopoiesis is restricted to the extravascular compartment of the BM by a single layer of BMEC that forms specialized vessels termed sinusoids. [47] [48] [49] [50] [51] [52] Thus, to enter or exit (mobilize) the hematopoietic compartment, HSCs must first recognize or to be recognized by the surface of the BM microvascular endothelial cells (BMEC). Molecules that mediate adhesion of HSC to BMEC are likely to play a pivotal role in the phenomenon of HSC mobilization.
HSC cell interactions with BMEC mimic similar pathways involved in leukocyte mobilization to inflamed tissues. [53] [54] [55] The initial phase of homing or mobilization of the HSC may be mediated through selectins, such as E-selectin, followed by firm adhesion mediated by VCAM1/VLA4 and ICAM1/LFA1 ligand pairs, and finally by interaction with interjunctional adhesion molecules such as PECAM ( Figure 2 , Table 1 ).
Using an in vitro transendothelial migration assay, we and others have shown that SDF-1-induced migration of HSC is mediated through interaction with E-selectin. 47, 48, [56] [57] [58] [59] [60] Other groups have shown that ICAM1/LFA1 51, 61, 62 and VCAM1/VLA4 [63] [64] [65] ligand pairs may play a key role in trafficking of HSC and CEPs.
Role of chemokines in the regulation of HSC trafficking
Selective homing of HSC to the BM is not only regulated by a specific set of adhesion molecules, but also by stem cell-active chemokines that are preferentially expressed within the BM microenvironment. 57, 66, 67 Chemokines provide directional cues for the HSC to settle within the BM (Figure 2 ). Stromal derived factor-1 (SDF-1) has been shown to provide the major chemotactic signals for localization of HSC to the BM. 66, [68] [69] [70] [71] CXCR4, the natural ligand for SDF-1, is expressed on HSC as well as CEPs.
72,73 SDF-1 is expressed at high levels by BM stromal cells and is believed to play a key role in chemoattracting and maintaining HSC within the BM. However, CXCR4 [74] [75] [76] [77] In addition, SDF-1 is necessary but not absolutely essential for HSC homing. 71, 78, 79 Therefore, other chemokines or cytokines may play key roles in stem cell trafficking. Since angiogenic receptors, such as VEGFR2 and Tie-2, are also expressed by HSC, we have explored the possibility that angiogenic factors with chemotactic potential, such as VEGF and angiopoietins, may also support mobilization of these types of stem cells.
Role of VEGF and its isoforms in the mobilization of HSCs and CEPs
VEGF is a homodimeric, heparin-binding glycoprotein that is produced by almost every cell type. 80 VEGF promotes angiogenesis by inducing proliferation, differentiation and chemotaxis of endothelial cells. 80, 81 It is remarkable that mice with only a single allele of the VEGF gene (VEGF+/Ϫ) die between days 11 and 12 in utero because of impaired hematopoiesis and angiogenesis. 82, 83 VEGFs include a family of distinct genes, which include placental growth factor (PLGF), [84] [85] [86] VEGF-B, 87 VEGF-C, 88 VEGF-D 89 and VEGF-E 90 ( Figure 3 ). Human VEGF-A is the most widely expressed and studied VEGF. 80 Human VEGF-A is encoded by a 14 kb, 8 exon gene, and is expressed in a variety of cells. 91 All VEGF 206 is the least common, observed only in human fetal liver. Residues in exons 6 and 7 are enriched in basic residues; these residues confer to longer forms (206 > 189 > 165, but not 121) the ability to bind to the extracellular matrix (ECM). 92 There are limited data comparing the biological function of each isoform. VEGF 121 is weakly acidic and does not bind to heparin, whereas VEGF 165 is basic and binds to heparin. VEGF 189 is even more basic and binds to heparin with more affinity. Therefore, VEGF 121 is soluble and has low affinity for ECM. 91, 92 In contrast, some of the secreted VEGF 165 is bound to the cell surface, but almost all VEGF 189 is bound to ECM. In the context of these observations, Advector delivery of the cDNAs for the various VEGF isoforms should yield different bioavailabilities compared with VEGF to the VEGF 165 that is conventionally used in experimental studies of angiogenesis. The VEGF 121 and VEGF 165 forms should provide an angiogenic molecule with chemotactic potential that is immediately available, 94 whereas VEGF 189 forms will bind to ECM, theoretically allowing for locoregional delivery of the Advectors and probably longer bioavailability.
Figure 3 VEGF family plays a critical role in the regulation of angiogenesis and hematopoiesis. VEGF-A is the most widely expressed angiogenic factor that support migration, survival and proliferation of endothelial cells through interaction with its tyrosine kinase receptors: VEGFR2 and VEGFR1. PLGF and VEGF-B exert their effect exclusively through interaction with VEGFR1. VEGFR1 is not only expressed on endothelial cells, but also on subsets of hematopoietic cells, including myelomonocytic and HSCs. VEGF-E which is expressed primarily by the Pox viruses, exert its effect only on VEGFR2.

Functional VEGF receptors are expressed on HSCs and CEPs
VEGF isoforms exert their biological effects through interaction with two tyrosine kinase receptors VEGFR2 (KDR human homologue, FLK-1 murine homologue) 95 and Flt-1 (VEGFR1) [96] [97] [98] ( Figure 3 ). Most studies have shown that VEGFR2 is the critical receptor for transmitting cellular signals for proliferation and differentiation and migration of endothelial cells, [96] [97] [98] while VEGFR1 may be more important for vascular remodeling. 99 Mice deficient in VEGFR2 have dramatic defects in vasculogenesis, angiogenesis and hematopoiesis. In contrast, VEGFR1 knockout mice develop abnormal vascular channels, suggesting a role for this receptor in the regulation of endothelial cell-matrix interactions. 99 Emerging data suggest that placental growth factor (PlGF) may also play a key role in regulation of angiogenesis. 86, 100, 101 One unique aspect of PlGF biology is that it uses exclusively VEGFR1 as the main signaling receptor and has no affinity for VEGFR2. Therefore, comparison of the effects of PlGF to those of VEGF isoforms will provide a unique opportunity to determine the relative significance of VEGFR1 and VEGFR2 in mobilization and expansion of CEPs and HSC.
Role of angiogenic factors in modulating the mobilization of HSCs and CEPs
Given the common prenatal origin of CEPs and HSCs, several survival and chemotactic signaling pathways are shared by both hematopoietic and vascular cells. VEGFR2 102 and Tie-2, 103 whose expression was believed originally to be restricted to endothelial cells, are also expressed by subsets of HSCs. Angiopoietin-1 (Ang-1), the natural ligand for Tie-2, 104 in conjunction with VEGF modulates different aspects of angiogenesis, such as remodeling [105] [106] [107] [108] and vascular permeability. 109 In addition, synergistic function of Ang-1 and VEGF plays an essential role in the development of hematopoiesis in the aorta-gonad-mesonephros (AGM) 110 by promoting the survival of endothelial and hematopoietic progenitor cells. 111 Although initial studies suggest that Angiopoietin-2 (Ang-2) may function as a natural antagonist of Ang-1, the exact function of Ang-2 is not known.
In addition to conveying signals that regulate cell proliferation, various isoforms of VEGF and Ang-1 also promote chemokinesis of endothelial cells and their progenitors. 107, 108 In certain physiological conditions, plasma levels of VEGF rapidly rise suggesting that these factors may function as acute phase chemokines to promote mobilization of stem cells, facilitating vascularization of various tissues.
Vascular trauma induce mobilization of BMderived CEPs
Under physiological conditions only a small amount of soluble bioavailable VEGF-A is detected in the peripheral circulation. However, vascular trauma results in plasma elevation of VEGF, which promotes recruitment of endothelial cells to the site of active angiogenesis. Vascular trauma as a result of surgical intervention or tissue injury induces the release of specific chemokines. Rapid recruitment of endothelial cells accelerates vascular healing and prevents potential vascular complications secondary to thrombosis or hypoxia. Similarly, tissue ischemia induced by myocardial infarction or cerebrovascular occlusion results in up-regulation of angiogenic factors including VEGF. VEGF and other released chemokines, including platelet derived growth factors (PDGF), fibroblast growth factor (FGF) and interleukin-8 promote mobilization and recruitment of endothelial cells to the site of the injury.
Two possible sources of endothelialization are: (1) endothelial migration 112, 113 from adjacent pre-existing blood vessels; and/or (2) recruitment of BM-derived CEPs from the peripheral circulation. 18, 20, 21 CEPs or BMresident EPCs can be considered embryonic angioblasts that migrate, proliferate and have the capacity to differentiate into mature endothelial cells. [114] [115] [116] There is ample evidence for the first scenario, however, the physiological significance of CEPs in the regulation of postnatal processes has recently been the subject of intensive scrutiny.
Several lines of evidence have suggested that vascular healing may be mediated in part by recruitment of CEPs. 22, 25 In these studies, it was demonstrated that genetically marked BM-derived endothelial-like cells were recruited to the ischemic limbs of mice, accelerating the revascularization process. Introduction of cytokines, such as G-CSF or GM-CSF, enhanced mobilization of the endothelial progenitors to the ischemic limbs augmenting the re-endothelialization process.
The physiological significance of the mobilization of CEPs were underscored in studies where thoracic aortae from adult dogs were replaced with Dacron grafts months after transplantation of a genetically haploidentical bone marrow. The Dacron grafts were made impervious by silicone coating to prevent ingrowth of endothelial cells. 21 After 3 months the re-endothelialized grafts were removed and the origin of endothelial cells colonizing the grafts were determined by micro-satellite PCR assays. Remarkably, endothelialization was shown to arise exclusively from the mobilized transplanted BM.
These data demonstrate that release of certain chemokine as a result of vascular injury results in mobilization of CEPs to the peripheral circulation. Denuded vascular bed coated with activated platelets and inflammatory cells, provide a permissive environment for the recruitment of these angio-competent progenitors accelerating the revascularization process.
In humans, evidence for the contribution of circulating endothelial cells to wound healing originates from patients implanted with a left ventricular assist device (LVAD). LVADs are implanted in patients with end-stage heart disease awaiting heart transplant. Implantation of LVADs results in a rapid recruitment of CEPs to these artificial coated surfaces, generating a non-thrombogenic surface. The LVAD removed 6 months after placement were colonized by CD34+VEGFR2+ endothelial and hematopoietic precursor cells, 19 suggesting that co-recruitment of endothelial and hematopoietic progenitors may be essential for formation of a non-thrombogenic vascular surface. Taken together, these studies suggest that a specialized population of VEGFR2+ endothelial cells residing in BM have the capacity to mobilize to the peripheral circulation and may contribute to rapid endothelialization and prevent thrombotic complications. In order to study the mechanism and efficacy of stem cellactive cytokines to induce mobilization HSCs and CEPs, we have used Advectors to challenge the potential of various stem cell-active chemokines to induce mobilization of pluripotent stem cells.
Use of adenoviral vectors for delivery of stem cell-active chemocytokine
Advectors are ideal for the functional delivery of chemocytokines for several reasons: (1) Generation of a physiological chemotactic gradient 117, 118 is most likely critical for the induction of chemokinesis and motility of stem cells; this is readily accomplished with chemokine gene delivery by Advectors, which can produce large titers of a chemokine or angiogenic factor in extramedullary sites to promote mobilization of BM-derived stem cells. 
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Mobilization of CEPs is regulated by VEGF/VEGFR2 signaling pathway and is essential for revascularization
Angiogenic switch necessitates up-regulation of angiogenic factors such as VEGF. Under steady state physiological conditions, VEGFR2+ CEPs represent only less than 0.01% of circulating mononuclear cells in the circulation. We have shown that plasma elevation of VEGF in
Figure 4 Adenoviral vectors (Advectors) are ideal vehicles to deliver physiological levels of chemokines for mobilization of stem cells. Intravenous injection of Advectors expressing various cytokines with chemotactic potential such as VEGF, angiopoietins, and a bona fide chemokine, such as SDF1 into mice results in the localization of the majority of these vectors to the mouse liver. The Advectors infect various liver cells, thereby rendering the liver as a bio-reactor where large quantities of a given chemokine are constitutively released into the peripheral circulation. Acute plasma elevation of the chemokines is sensed by the stem cells within the BM, initiating the process of mobilization and recruitment to the peripheral circulation.
intact adult mice by recombinant protein or Advector gene delivery, results in the mobilization of VEGFR2+ CEPs. [18] [19] [20] 125 In humans VEGFR2+ CEPs also express another hemangiogenic stem cell marker, AC133, which its expression diminishes very rapidly upon maturation of stem cells.
Using Advectors to increase the plasma levels of various VEGF isoforms, we demonstrated that AdVEGF 165 induced mobilization of a significant number of CEPs to the peripheral blood ( Figure 5 ). Mobilized CEPs can be distinguished from mature endothelial cells by their capacity to form late outgrowth colonies (CFU-EC). In contrast to mature endothelial cells, which form early outgrowth colonies, CEPs form rapidly proliferating endothelial colonies 3 to 4 weeks after initiation of the culture. Incubation of mobilized VEGFR2+ PBMCs with VEGF and FGF-2 (basic-FGF) on collagen-coated plastic dishes resulted in the generation of early, as well as late outgrowth DiI-Ac-LDL+ endothelial cells (CFU-EC). The majority of the colonies formed were comprised of late outgrowth endothelial cells, suggesting that VEGF and Ang-1 promote the mobilization of BM derived CEPs.
We have also shown that vascular trauma induced by burn injury or surgical manipulation results in rapid mobilization of AC133+VEGFR2+ CEPs. 126 Six hours after vascular trauma, CEPs can be detected in the peripheral circulation. Remarkably, 24 h after vascular injury, 12% of the total circulating peripheral mononuclear cells comprised of VEGFR2+AC133+ cells. Mobilization of CEPs was paralleled with plasma elevation of VEGF, suggesting that VEGF released as a result of vascular injury promote mobilization of CEPs. These data are consistent with chemokine-driven recruitment of BM-derived precursor cells that restore angiogenesis in ischemic limbs. 25 We have taken advantage of the angiogenesis defect in Id-mutant mice to challenge the necessity of BM-derived CEPs in supporting tumor growth. In contrast to wildtype mice, Id-mutant mice fail to support the growth of tumors because of impaired angiogenesis. However, transplantation of BM-derived cells from wild-type mice can restore the angiogenic defect and tumor growth in otherwise tumor-resistant Id mutant mice. 2 Further analysis has demonstrated that the main defect in Id mutant mice is the impaired VEGF-induced mobilization of CEPs. These data suggest that mobilization of marrowderived endothelial, as well as hematopoietic cells including HSCs are essential for postnatal revascularization processes. In this regard, identification of factors that promote mobilization of HSCs or subset of hematopoietic cells will not only provide a means to isolate a large number of HSCs, but also define the mechanism by which stem cells undergo proliferation and are mobilized to circulation.
Elevation of plasma levels of angiogenic factors results in mobilization of hematopoietic cells with marrow repopulating potential
CXCR4, the chemokine receptor for SDF-1, is expressed on HSC and CEPs. The capacity of mobilized hematopoietic cells to form CFU-S and repopulate lethally irradiated hosts provide functional means to assess the pluripotency of mobilized circulating cells. Injection of Advectors expressing SDF-1 (AdSDF-1) promotes mobilization of large numbers of cells with CFU-S, as well as of cells with BM repopulating capacity. 127 Plasma elevation of VEGF 165 also results in the mobilization of HSCs. Administration of AdVEGF 165 into SCID mice, resulted in peak plasma levels of VEGF 24 h after injection and a decline to pretreatment level at day 35.
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Doses above 1 × 10 8 p.f.u. were toxic and resulted in demise of the treated mice. In order to examine the effect of VEGF 165 overexpression in the peripheral circulation on mobilization of HSCs, SCID mice were injected with 10 8 p.f.u. of AdVEGF and/or 10 9 p.f.u. of AdAng-1. Subsequently, the number of mobilized HSC capable of forming spleen colonies (CFU-S) and repopulating BM cells were also measured by injecting AdVEGF 165 or AdNull mobilized mononuclear cells into irradiated mice (Figure  6a and b) . The administration of AdVEGF 165 caused a 20-fold increase in peripheral blood CFU-S, 5 days after the onset of treatment. In contrast, the administration of AdAng-1 caused a 2.5-fold increase in peripheral blood CFU-S, 14 days after injection. Treatment with both AdVEGF 165 and AdAng-1 showed synergistic effects on the number of mobilized cells with CFU-S potential.
One of the unique features of HSC is their capacity to reconstitute lethally irradiated mice. The number of mobilized pluripotent hematopoietic cells with BM-repopulating capacity was also determined by allogeneic transplantation of either VEGF 165 or Ang-1 mobilized cells into lethally irradiated MHC mismatched mice. Injection of either VEGF 165 or Ang-1, but not AdNull, resulted in mobilization of HSC that were able to engraft and rescue lethally irradiated mice (Figure 6c ). These data suggest that overexpression of soluble VEGF 165 and Ang-1 induces mobilization of pluripotent HSCs from BM to the peripheral circulation. 
u.), were delivered by a single intravenous (i.v.) administration on day 0. (a) Total white blood cells were counted using a Neubauer hematocytometer and stained by crystal violet (n = 6). The pluripotency of the mobilized cells was determined by CFU-S assay (b) and BM repopulating assay (c). As compared with
Regulation of mobilization of HSCs and CEPs
Chemokine-mediated mobilization of HSCs and CEPs is a dynamic process and is mediated through sequential activation and up-regulation of certain adhesion molecules and metalloproteinases. VEGF-induced up-regulation of specific metalloproteinases including MMP-9, may be essential to provide a permissive environment within the BM to facilitate mobilization of CEPs and hematopoietic precursors. It is intriguing that VEGFR2+ CEPs and VEGFR1+ hematopoietic precursor cells were mobilized and incorporated into the tumor vascular bed within the first 48 h of tumor inoculation. The necessity for the mobilization of VEGFR2 CEPs in restoring tumor angiogenesis is highlighted by the finding that VEGF-induced mobilization of CEPs is completely impaired in Idmutant mice. We also demonstrated that inoculation of tumor tissue results in release of chemokines that promote mobilization of VEGFR2+ CEPs, confirming the results obtained with VEGF mobilization. Similar to the impairment observed with VEGF-induced mobilization of CEPs, inoculation of B6RV2 into Id mutant mice was associated with complete impairment in mobilization of VEGFR2+ CEPs. 2 The significance of VEGF-mediated mobilization of precursor cells is further underscored in Gene Therapy the study where transplantation of Id mutant BM into wild-type mice resulted in a profound delay in tumor growth. These results suggest that failure of Id mutant BM-derived precursor cells to get mobilized to tumor vasculature, in an otherwise angio-competent host, is the primary defect in retarded tumor angiogenesis.
Mobilization of CEPs and HSCs requires activation of metalloproteinases
During steady state conditions, the majority of stem cells within the BM reside in close cellular association with stromal cells, but are inaccessible to vasculature. Therefore, chemokine-activated HSCs and CEPs destined for mobilization have to find their way through extracellular matrix and approach sinusoidal endothelial cells to get mobilized to the peripheral circulation. In this regard, activation of metalloproteinases may be essential to facilitate mobility of CEPs and HSCs (Figure 7) . Moreover, reactivation of certain tethered membrane-bound factors may be essential to enhance the motility of stem cells. We have shown that BM suppression results in activation and overexpression of matrix metalloproteinase-9, (MMP-9, gelatinase-B) by hematopoietic, as well as BM stromal cells. In fact, MMP inhibitors effectively block mobilization of HSCs and CEPs. Chemokine-driven mob- ilization of hematopoietic progenitors was partially blocked, while mobilization of stem cells was completely inhibited in MMP-9-deficient mice. MMP-9-deficient mice also displayed delayed hematopoietic reconstitution following treatment with the BM suppressive agent 5-fluorouracil (unpublished results). These data suggest that MMP-9 activation is essential for trafficking of HSCs and CEPs, thereby supporting reconstitution of stem and progenitor cell pool after BM ablation.
Conclusions
Embryonic stem cells are an abundant source of tissuespecific stem cells. However, given the bio-ethical issues involved in the use of human embryonic stem cells and tissues, other sources of pluripotent stem cells may be considered for use in promoting tissue regeneration and gene therapy. Adult stem cells provide an alternative source of multi-potential stem cells that can be used for tissue regeneration and vascularization. However, since the number of stem cells in adult BM or tissues is very low, strategies to facilitate expansion and mobilization of stem cells will significantly enhance our ability to isolate a large population of stem cells that may ultimately be used for genetic manipulation and in vitro expansion.
Using Advector gene delivery of trangenes with chemotactic potential, we have demonstrated that plasma elevation of stem cell-active chemokines including SDF-1, VEGF 165 and Ang-1 results in robust mobilization of CEPs and HSCs (CFU-S, BM repopulating cells), to the peripheral circulation. The overexpression of VEGF 165 induces a very rapid (24 to 48 h) mobilization of CEPs and HSCs suggesting that the effect of VEGF 165 seems to be mediated through a chemokinetic process.
Mobilization of CEPs to the peripheral circulation may play a critical role in regulating post-natal angiogenesis and vasculogenesis. High levels of VEGF produced by the tumors or after acute vascular injury, result in the mobilization of BM-derived CEPs to the peripheral circulation accelerating the revascularization process. Given that CEPs may also contribute to vascular healing, overexpression of VEGF 165 may promote the peripheral blood mobilization and recruitment of CEPs to the injured vascular bed, thereby accelerating wound healing.
Understanding the kinetic and the exact mechanism of the mobilization of stem cells allows development of strategies in which a large number of pluripotent stem cells can be mobilized and harvested from the peripheral circulation. These cells can be expanded on stromal cells for delivery for tissue regeneration or alternatively, genetically manipulated for use in the treatment of congenital disorders. Advector delivery of chemokines will facilitate studies to dissect the mechanism by which stem cells are mobilized to the circulation. In addition, these murine mobilization models provide an ideal in vivo bio-assay to identify organ-specific chemokines that promote mobilization of tissue-specific stem cells.
